Neoadjuvant Endocrine Therapy: Who Benefits Most?

Julie Grossman; Cynthia Ma; Rebecca Aft

doi:10.1016/j.soc.2017.07.008

Neoadjuvant Endocrine Therapy: Who Benefits Most?

Surg Oncol Clin N Am. 2018 Jan;27(1):121-140. doi: 10.1016/j.soc.2017.07.008.

Authors

Julie Grossman¹, Cynthia Ma¹, Rebecca Aft²

Affiliations

¹ Department of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA.
² Department of Surgery, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA. Electronic address: Aftr@wudosis.wustl.edu.

PMID: 29132556
DOI: 10.1016/j.soc.2017.07.008

Abstract

Neoadjuvant endocrine therapy (NET) can be effective at downstaging patients with estrogen receptor-positive tumors and identifying those tumors that are endocrine sensitive and resistant. The optimal prognostic markers for stratification are under investigation. Use of NET will allow the identification of patients with estrogen receptor-positive tumors who might benefit from additional treatment and allow better understanding of endocrine resistance.

Keywords: Aromatase inhibitors; Estrogen receptor–positive breast cancer; Neoadjuvant chemotherapy; Neoadjuvant endocrine therapy.

Publication types

Review

MeSH terms

Antineoplastic Agents, Hormonal / therapeutic use*
Breast Neoplasms / drug therapy*
Chemotherapy, Adjuvant / methods*
Estrogen Receptor Modulators / therapeutic use*
Female
Humans
Neoadjuvant Therapy / methods*

Substances

Antineoplastic Agents, Hormonal
Estrogen Receptor Modulators